PL2249821T3 - Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków - Google Patents

Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków

Info

Publication number
PL2249821T3
PL2249821T3 PL09705303T PL09705303T PL2249821T3 PL 2249821 T3 PL2249821 T3 PL 2249821T3 PL 09705303 T PL09705303 T PL 09705303T PL 09705303 T PL09705303 T PL 09705303T PL 2249821 T3 PL2249821 T3 PL 2249821T3
Authority
PL
Poland
Prior art keywords
carboxylic acid
acid esters
hydroxyguanidine
amidoxime
producing prodrugs
Prior art date
Application number
PL09705303T
Other languages
English (en)
Inventor
Bernd Clement
Christiane Reeh
Helen Hungeling
Original Assignee
Dritte Patentportfolio Beteili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteili filed Critical Dritte Patentportfolio Beteili
Publication of PL2249821T3 publication Critical patent/PL2249821T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/62Oximes having oxygen atoms of oxyimino groups esterified
    • C07C251/64Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
    • C07C251/66Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids with the esterifying carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL09705303T 2008-02-01 2009-02-02 Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków PL2249821T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008007381A DE102008007381A1 (de) 2008-02-01 2008-02-01 Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
EP09705303.7A EP2249821B1 (de) 2008-02-01 2009-02-02 Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs
PCT/EP2009/051132 WO2009095499A1 (de) 2008-02-01 2009-02-02 Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs

Publications (1)

Publication Number Publication Date
PL2249821T3 true PL2249821T3 (pl) 2015-12-31

Family

ID=40532565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09705303T PL2249821T3 (pl) 2008-02-01 2009-02-02 Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków

Country Status (20)

Country Link
US (2) US20110028756A1 (pl)
EP (3) EP2985021A1 (pl)
JP (2) JP2011510956A (pl)
KR (1) KR20100110875A (pl)
CN (1) CN101951897B (pl)
AU (1) AU2009209560B2 (pl)
BR (1) BRPI0906569A2 (pl)
CA (1) CA2713784C (pl)
CY (1) CY1116801T1 (pl)
DE (1) DE102008007381A1 (pl)
DK (1) DK2249821T3 (pl)
ES (1) ES2547117T3 (pl)
HR (1) HRP20150961T1 (pl)
HU (1) HUE026276T2 (pl)
IL (1) IL207286A0 (pl)
PL (1) PL2249821T3 (pl)
PT (1) PT2249821E (pl)
SI (1) SI2249821T1 (pl)
WO (1) WO2009095499A1 (pl)
ZA (1) ZA201004767B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
DK2550963T3 (en) * 2011-07-25 2017-01-30 Dritte Patentportfolio Beteili Pentamidine amidoxime acid esters as prodrugs and their use as a drug.
PT2550966T (pt) 2011-07-25 2017-01-31 Dritte Patentportfolio Beteili Ésteres de ácido carboxílico de amidoxima de dabigatrana como pró-drogas e utilização das mesmas como medicamento
ES2416004B1 (es) * 2012-01-24 2014-01-28 Investigaciones Farmaceuticas Y Veterinarias, S.L. Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales.
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
US9375411B2 (en) 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
CN106831611B (zh) * 2017-01-23 2019-06-21 北京化工大学 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
AU7130101A (en) * 2000-06-14 2001-12-24 Corixa Corp Enzyme-cleavable prodrug compounds
EP1404356B1 (en) * 2001-06-11 2011-04-06 Medarex, Inc. Method for designing cd10-activated prodrug compounds
EP1482940A2 (en) 2001-10-03 2004-12-08 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
ES2393924T3 (es) * 2004-06-30 2013-01-02 Toyama Chemical Co., Ltd. Derivado de arilamidina, sal del mismo y antifúngico que lo contiene
DE102006034256A1 (de) * 2006-07-21 2008-01-31 Christian-Albrechts-Universität Zu Kiel Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
US20110028756A1 (en) 2011-02-03
DE102008007381A1 (de) 2009-08-13
CA2713784A1 (en) 2009-08-06
DK2249821T3 (en) 2015-10-05
BRPI0906569A2 (pt) 2015-07-07
PT2249821E (pt) 2015-10-13
AU2009209560A1 (en) 2009-08-06
JP2011510956A (ja) 2011-04-07
US20140350293A1 (en) 2014-11-27
CN101951897A (zh) 2011-01-19
HRP20150961T1 (hr) 2015-11-06
KR20100110875A (ko) 2010-10-13
CY1116801T1 (el) 2017-03-15
HK1153144A1 (zh) 2012-03-23
WO2009095499A1 (de) 2009-08-06
EP2985021A1 (de) 2016-02-17
ZA201004767B (en) 2011-04-28
US9353047B2 (en) 2016-05-31
JP2016193927A (ja) 2016-11-17
CN101951897B (zh) 2016-01-20
EP2249821A1 (de) 2010-11-17
EP2732816A1 (de) 2014-05-21
HUE026276T2 (en) 2016-06-28
ES2547117T3 (es) 2015-10-01
SI2249821T1 (sl) 2015-12-31
EP2249821B1 (de) 2015-07-29
IL207286A0 (en) 2010-12-30
CA2713784C (en) 2016-09-27
AU2009209560B2 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
IL207286A0 (en) Use of amidoxime carboxylic acid esters and n - hydroxyguanidine carboxylic acid esters for producing prodrugs
SG10201610916SA (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PL2352497T3 (pl) Proces przygotowania estrów aminokwasowych delta-9-thc
PL2184270T3 (pl) Katalizowane zeolitem wytwarzanie związków alfa-hydroksykwasów karboksylowych i ich estrów
ZA201100528B (en) Method for the synthesis of bioresourced acrylic acid esters
BRPI1012744A2 (pt) "processo contínuo para preparação de ésteres de ácidos carboxílicos alifáticos"
SG10201402443PA (en) Isoxazolines As Inhibitors Of Fatty Acid Amide Hydrolase
ZA201103085B (en) Method for the synthesis of an omega-amino acid or ester starting from a monounsaturated fatty acid or ester
ZA201206168B (en) A process for the enzymatic synthesis of fatty acid alkyl esters
IL224955A (en) Morphic forms of phosphonic acid esters and methods for their synthesis
EP2325166A4 (en) METHOD FOR INHIBITING THE POLYMERIZATION OF AN ISOCYANATE-GROUP-CONTAINING ETHYLENE DISCOVERY CARBOXYLIC ACID ESTER COMPOUND, AND METHOD FOR PRODUCING AN ETHYLENE-UNSATURATED CARBOXYLIC ACID ESTER COMPOUND CONTAINING AN ISOCYANATE GROUP
PL2358851T3 (pl) Zastosowanie kwasu metanosulfonowego do wytwarzania estrów kwasów tłuszczowych
LT2550966T (lt) Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų
IL215870A0 (en) Processes for purification of 1-methylpyrzole-4-carboxylic acid esters
LT2550963T (lt) Pentamidino-amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų naudojimas kaip vaistų
IL201584A0 (en) Process for the preparation of pure acrylate esters
ZA201107378B (en) Process for the preparation of a biphenyl-2ylcarbamic acid ester
IL230860A (en) A process for the production of an acidic cyclopropanecarboxylic ester compound
PL388460A1 (pl) Nowe estry kwasu borowego oraz nowy sposób otrzymywania estrów kwasu borowego